Amjevita Dosing & Administration Guide

About This Information

This content supports the Amjevita Dosing Calculator by providing context on its outputs, usage, and the clinical data it is based upon. All information is aligned with the U.S. Prescribing Information and should be used by qualified healthcare providers to guide treatment decisions.

Understanding the Calculator Outputs

The calculator provides a patient-specific dosing regimen based on the inputs provided. The output typically includes:

• Induction Dose: The initial, higher dose required for certain conditions like Crohn’s Disease, Ulcerative Colitis, and Hidradenitis Suppurativa to rapidly achieve therapeutic levels.
• Maintenance Dose: The ongoing, regular dose administered after the induction phase to maintain therapeutic effect.
• Dosing Schedule: The frequency of administration, such as weekly, every other week, or as a multi-day induction series.
• Administration Route: Clarifies that Amjevita is administered via subcutaneous injection.
• Available Formulations: Lists the available strengths and delivery devices to aid in prescription and administration planning.

How to Use the Calculator

To obtain a recommended dosing regimen, follow these steps using the tool above:

1. Select Patient Population: Choose between “Adult (≥18 years)” and “Pediatric (<18 years)”. This is the primary filter for available indications.
2. Select Indication: From the dropdown menu, choose the specific FDA-approved indication for which you are treating the patient.
3. Enter Patient Weight: If treating a pediatric patient, the weight field will appear. Enter the patient’s weight and select the correct units (kg or lb), as dosing for all pediatric indications is weight-based.
4. Calculate: The tool will display the recommended induction (if applicable) and maintenance dosing schedule.

Dosing Overview

Dosing for Amjevita varies significantly by indication and patient population. Below is a summary of common regimens:

• Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (Adults): The standard maintenance dose is 40 mg every other week. No induction dose is required.
• Crohn’s Disease, Ulcerative Colitis (Adults): A two-stage induction is required, starting with 160 mg on Day 1, followed by 80 mg on Day 15. The maintenance dose is 40 mg every other week starting on Day 29.
• Plaque Psoriasis (Adults): An initial dose of 80 mg is given, followed by a maintenance dose of 40 mg every other week starting one week later.
• Juvenile Idiopathic Arthritis (Pediatrics ≥2y): Dosing is weight-based, ranging from 10 mg to 40 mg every other week. No induction dose is required.

Switching from a Reference Product

Patients may be switched from a reference adalimumab product to Amjevita. Healthcare providers should follow the guidance in the full Prescribing Information. Typically, patients can be transitioned at the time of their next scheduled dose, continuing the same dosing regimen. Clinical judgment is essential to ensure a smooth transition.

Missed Dose Instructions

If a patient misses a dose of Amjevita, they should be advised to inject the missed dose as soon as they remember. They should then take their next dose at the regularly scheduled time. This will re-establish their original administration schedule. Patients should not take two doses at the same time.

Safety Alerts

Frequently Asked Questions (FAQ)

• What is the difference between induction and maintenance dosing?
  An induction dose is a higher initial dose used to quickly achieve therapeutic drug levels, common in conditions like IBD. A maintenance dose is the lower, regular dose used to maintain those levels long-term.
• Does the calculator account for concomitant methotrexate (MTX) use?
  The calculator provides the standard Amjevita dose based on its PI. The notes in the output may mention that Amjevita can be used with or without MTX for RA, but it does not alter the dose itself.
• How is pediatric dosing for Juvenile Idiopathic Arthritis (JIA) determined?
  For JIA, the dose is based on body weight. The calculator automatically selects the correct dose (10 mg, 20 mg, or 40 mg every other week) based on the weight category entered.
• What are the available strengths of Amjevita?
  As listed by the calculator, Amjevita is available in prefilled autoinjectors or syringes with strengths of 80 mg, 40 mg, 20 mg, and 10 mg to accommodate various dosing regimens.
• Can this calculator be used for off-label indications?
  No. This tool is strictly for educational purposes and calculates doses based only on the FDA-approved indications listed in the U.S. Prescribing Information.
• What if a patient’s weight is just below a dosing threshold?
  The dosing thresholds are based on clinical trial data. Always use clinical judgment, but the calculator will recommend the dose corresponding to the weight bracket the patient falls into per the PI.
• Does the calculator provide guidance for dose escalation due to lack of efficacy?
  The tool primarily calculates the standard approved dosing. For some conditions like Plaque Psoriasis, the official PI notes that increasing the frequency to 40 mg weekly may be considered, which is reflected in the calculator’s output notes.
• Why does the calculator require weight for pediatric but not most adult indications?
  Dosing for approved pediatric indications is weight-based to ensure proper exposure in a growing body. Most adult indications use a fixed dose that has been proven effective and safe across a wide range of adult body weights.

References

This information is based on the following high-authority sources. Always refer to the most current full Prescribing Information before making clinical decisions.

• Amjevita (adalimumab-atto) Full Prescribing Information. U.S. Food and Drug Administration. May 2024.
• Amjevita® (adalimumab-atto) Healthcare Professional Site. Amgen Inc.
• IBD Medication Guide. Crohn’s & Colitis Foundation.
• Clinical Practice Guidelines for Rheumatoid Arthritis. American College of Rheumatology.